TD Cowen analyst Daniel Brennan has maintained their bullish stance on NTRA stock, giving a Buy rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Daniel Brennan has given his Buy rating due to a combination of factors that highlight Natera’s strong performance and growth potential. The company reported impressive sales results, surpassing expectations by 13%, driven by core growth and favorable prior period developments. Notably, the clinical volume for Signatera showed significant growth, exceeding both quarterly and yearly expectations, which is likely to be positively received by the market.
Additionally, Natera’s Women’s Health and Transplant segments also delivered strong results, contributing to the overall upside. The management’s discussion of upcoming clinical data read-outs and the potential for new guidelines further supports the company’s growth prospects. The market for Natera’s offerings is rapidly expanding, yet still underpenetrated, which positions the company well against future competition. The raised sales guidance for 2025, along with continued investment in clinical trials and sales force expansion, indicates confidence in sustained growth, supporting the Buy recommendation.
In another report released today, Barclays also maintained a Buy rating on the stock with a $190.00 price target.